Shots:
- Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets
- As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development & sales milestones plus royalties on licensed therapeutics. Further terms are not disclosed
- In addition, the company has secured $62M in Series A funding led by Versant Ventures, with Mubadala Capital, BMS, Taiho Ventures & AbbVie
Ref: Businesswire | Image: Novartis & Light Horse
Related News:- PTC Therapeutics Join Forces with Novartis to Develop PTC518 for Treating Huntington’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
